Lipid Screening, Action, and Follow-up in Children and Adolescents

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pediatrics

Background:

• Familial hypercholesterolaemia (FH) is a genetic disorder characterized by high LDL-C levels.
• Individuals with FH have a substantially increased risk of premature cardiovascular disease (CVD).
• Early detection and intervention are crucial to mitigate the long-term impact of FH.

Purpose of the Study:

• To raise awareness about the severe effects of high cholesterol in FH on blood vessels.
• To emphasize the importance of early diagnosis and treatment of FH.
• To highlight the potential to prevent significant atherosclerotic damage later in life.

Main Methods:

• Review of current and emerging therapeutic strategies for FH in pediatric populations.
• Discussion of diagnostic advancements, including next-generation sequencing.
• Analysis of treatment efficacy and safety profiles of available and novel medications.

Main Results:

• Statins are effective in children as young as 6 years, normalizing intima-media thickness within 2 years.
• Newer, potentially more effective drugs with favorable safety profiles are anticipated for pediatric use.
• Next-generation sequencing may aid in identifying individuals requiring treatment and those at risk for adverse effects.

Conclusions:

• Early statin therapy in children with FH can effectively manage high LDL-C and prevent vascular damage.
• Future advancements in pharmacotherapy and genetic sequencing promise improved management of FH in pediatric patients.
• Recommendations for the treatment of children and adolescents with heterozygous FH are provided.